Drug Target Review
OCTOBER 4, 2023
Groundbreaking strategies like proteolysis-targeting chimeric molecules (PROTACs) are also being explored. 6 Combining the effect of payloads with different mechanisms of action – an approach that revolutionised small molecule chemotherapy – also holds the promise of enhanced therapeutic activity for ADCs. 12 , 2955–2960 (2006).
Drug Target Review
JUNE 19, 2024
Transplanting cells could prove to be more beneficial than treating a particular condition with a small molecule or an antibody, and that really speaks to the power of cell therapy. Just like small molecules and antibodies, cell therapies are changing how we treat patients. SVRA) in April 2017.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Drug Target Review
NOVEMBER 1, 2023
2017 Mar 9;60(5):2006–17. Structure–Activity Relationships of Small Molecule Autotaxin Inhibitors with a Discrete Binding Mode. Keune WJ, Potjewyd F, Heidebrecht T, et al. Rational Design of Autotaxin Inhibitors by Structural Evolution of Endogenous Modulators. J Med Chem. Miller LM, Keune WJ, Castagna D, et al. J Med Chem.
Drug Target Review
JUNE 12, 2023
The current version of Chemistry42 uses over 40 generative models, including generative autoencoders and generative adversarial networks as well as both structure-based and ligand-based drug design to generate and optimise de novo small molecules.
The Premier Consulting Blog
JULY 9, 2023
During the development of new small molecule drug products, developers must conduct impurity and degradant evaluation at several points in the program and to varying degrees. These evaluations include the active pharmaceutical ingredient (API), also known as the drug substance, and the drug product (formulated product).
PLOS: DNA Science
JUNE 22, 2023
The candidate drug, vorasidenib, is a small molecule that inhibits survivin. Gleevec came from a massive effort throughout the 1980s to screen more than 400 small molecules for one that would block the activity of the errant tyrosine kinase, without derailing other important enzymes. It is a cyclin-dependent kinase.
The Pharma Data
OCTOBER 19, 2020
At Aduro, he was responsible for all manufacturing and supply chain activities for the company’s biologics and small molecules and managed a transatlantic team. USA) from the period of 2006 to 2016. Prior to Aduro, Dr. van de Laar held various development and manufacturing positions at MSD (trademark of Merck & Co.,
Expert insights. Personalized for you.
126 
Let's personalize your content